[go: up one dir, main page]

DK3286183T3 - Isoxazolylsubstituerede benzimidazoler - Google Patents

Isoxazolylsubstituerede benzimidazoler Download PDF

Info

Publication number
DK3286183T3
DK3286183T3 DK16718863.0T DK16718863T DK3286183T3 DK 3286183 T3 DK3286183 T3 DK 3286183T3 DK 16718863 T DK16718863 T DK 16718863T DK 3286183 T3 DK3286183 T3 DK 3286183T3
Authority
DK
Denmark
Prior art keywords
isoxazolyl
substituted benzimidazoles
benzimidazoles
substituted
Prior art date
Application number
DK16718863.0T
Other languages
English (en)
Inventor
Neil Anthony Pegg
David Michel Adrien Taddei
Stuart Thomas Onions
Eric Sing Yuen Tse
Richard James Brown
David Kenneth Mycock
David Cousin
Anil Patel
Original Assignee
Cellcentric Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellcentric Ltd filed Critical Cellcentric Ltd
Application granted granted Critical
Publication of DK3286183T3 publication Critical patent/DK3286183T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK16718863.0T 2015-04-20 2016-04-20 Isoxazolylsubstituerede benzimidazoler DK3286183T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506658.2A GB201506658D0 (en) 2015-04-20 2015-04-20 Pharmaceutical compounds
PCT/GB2016/051088 WO2016170324A1 (en) 2015-04-20 2016-04-20 Isoxazolyl substituted benzimidazoles

Publications (1)

Publication Number Publication Date
DK3286183T3 true DK3286183T3 (da) 2021-09-20

Family

ID=53298840

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16718863.0T DK3286183T3 (da) 2015-04-20 2016-04-20 Isoxazolylsubstituerede benzimidazoler

Country Status (9)

Country Link
US (1) US10118920B2 (da)
EP (1) EP3286183B1 (da)
JP (1) JP6871864B2 (da)
CN (1) CN107750249A (da)
DK (1) DK3286183T3 (da)
ES (1) ES2888473T3 (da)
GB (1) GB201506658D0 (da)
HU (1) HUE056334T2 (da)
WO (1) WO2016170324A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
JP6912039B2 (ja) 2015-08-12 2021-07-28 ネオメド インスティテュートNeomed Institute 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
TWI846350B (zh) 2017-09-15 2024-06-21 美商佛瑪治療公司 作為CBP/p300抑制劑之四氫-咪唑並喹啉化合物
RU2020131507A (ru) 2018-03-29 2022-05-04 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
US10899769B2 (en) 2018-04-06 2021-01-26 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
MX2020014303A (es) 2018-06-29 2021-03-25 Forma Therapeutics Inc Inhibición de la proteína de union a creb (cbp).
AR118362A1 (es) 2019-03-15 2021-09-29 Forma Therapeutics Inc Inhibición de la proteína de unión al elemento de respuesta a amp cíclico (creb)
JP7626721B2 (ja) * 2019-06-18 2025-02-04 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド 小分子標的ブロモ/アセチルタンパク質およびその使用
CN112574189B (zh) 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
KR20230028512A (ko) 2020-06-25 2023-02-28 톨레모 테라퓨틱스 아게 EGFR-돌연변이 NSCLC의 치료에 사용하기 위한 CBP/p300 브로모도메인 억제제 및 EGFR 억제제의 조합물
US20230233558A1 (en) 2020-06-25 2023-07-27 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
CN112250672B (zh) * 2020-10-21 2022-06-21 清华大学深圳国际研究生院 一种核苷碱基衍生物及其制备方法和应用
US20240109879A1 (en) * 2020-12-31 2024-04-04 Medshine Discovery Inc. Benzimidazole compound and application thereof
CN115716822B (zh) * 2022-11-14 2025-05-16 徐州医科大学 苯并咪唑基异噁唑类化合物在制备与多发性骨髓瘤有关药物方面的应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
WO1990012321A1 (en) 1989-03-31 1990-10-18 The Cancer Institute Board Halogenated dna ligand radiosensitisers for cancer therapy
US5667975A (en) 1994-05-06 1997-09-16 The University Of North Carolina Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans
US5968933A (en) 1994-08-26 1999-10-19 Auckland Division Cancer Society Of New Zealand Inc. DNA-targeted alkylating agents
US5668166A (en) 1995-06-07 1997-09-16 Georgia State University Research Foundation, Inc. Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
CA2283057A1 (en) 1997-02-05 1998-08-06 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
IL137351A0 (en) 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
JP4507026B2 (ja) 1999-04-06 2010-07-21 東洋紡績株式会社 ハレーション防止用組成物およびそれを用いた感光性樹脂積層体
IL146125A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Novel quinones as disease therapies
AU1399801A (en) 1999-11-05 2001-05-14 Aventis Pharma S.A. Oligobenzimidazole derivatives and their use as dna transfection agents
CA2392150A1 (en) 1999-12-20 2001-06-28 The University Of North Carolina At Chapel Hill Diamidine compounds as dna minor groove binders
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
DE60222899T2 (de) 2001-01-13 2008-08-14 Auburn University, Auburn Verbindungen, verfahren und zusammensetzungen für die behandlung von infektionen mit dem rinderdiarrhö-virus (bvdv) und dem hepatitis-c-virus (hcv)
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
WO2003017994A1 (en) 2001-08-31 2003-03-06 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2004024114A (ja) 2002-06-26 2004-01-29 Shigeori Takenaka 電気化学的二本鎖dna検出試薬としての新規インターカレータ
EP1529045A2 (en) 2002-08-09 2005-05-11 Astra Zeneca AB New compounds
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
KR20060054410A (ko) 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 플라비비리다에에 대한 2고리 이미다졸 유도체
US20070088067A1 (en) 2003-09-05 2007-04-19 Tidwell Richards R Novel amidine compounds for treating microbial infections
EP1692085A4 (en) 2003-11-07 2010-10-13 Novartis Vaccines & Diagnostic INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA
AU2005214225B2 (en) 2004-02-19 2010-05-20 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative
US8097238B2 (en) 2004-02-27 2012-01-17 Peter Maccallum Cancer Institute Cell targeting conjugates
US20070276020A1 (en) 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
CA2579889A1 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
CA2579313A1 (en) 2004-09-17 2006-03-30 Exelixis, Inc. Pyrazole kinase modulators and methods of use as c-kit or fit-3 kinase inhibitors
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
ATE548363T1 (de) 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
DK2114896T3 (da) 2006-12-21 2015-10-26 Peter Maccallum Cancer Inst Strålebeskyttende forbindelser og tilknyttede fremgangsmåder
EP2139474A2 (en) 2007-03-27 2010-01-06 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
GB0707934D0 (en) 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US7662526B2 (en) 2007-05-04 2010-02-16 Xerox Corporation Photoconductors
US8198307B2 (en) 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
JP2009005594A (ja) 2007-06-26 2009-01-15 Kyoto Univ 遺伝子診断機能性蛍光色素の製造方法
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Hcv ns5a의 억제제
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
ES2787599T3 (es) 2009-05-13 2020-10-16 Univ Virginia Patent Foundation Inhibidores de leucemia inv(16)
EP2455376B1 (en) 2009-06-11 2014-11-26 AbbVie Bahamas Ltd. Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2767764A1 (en) 2009-07-13 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9072761B2 (en) 2009-08-14 2015-07-07 Clemson University Research Foundation (Curf) Methods and compositions related to viral inhibition
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CN103038237A (zh) 2010-03-24 2013-04-10 沃泰克斯药物股份有限公司 用于黄病毒感染治疗或预防的类似物
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
EP2621915B1 (en) 2010-09-28 2016-04-20 Daewoong Pharmaceutical Co., Ltd Novel method of preparing benzoimidazole derivatives
WO2012044567A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
CA2819894A1 (en) 2010-12-16 2012-06-21 Abbvie Inc. Anti-viral compounds
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
JP2014509660A (ja) 2011-04-01 2014-04-21 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション PDK1キナーゼの阻害剤としての置換3−(1H−ベンゾ{d}イミダゾール−2−イル)−1H−インダゾール類似体
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
CA2837207A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
WO2013036749A1 (en) 2011-09-07 2013-03-14 University Of Kansas Hcv helicase inhibitors and methods of use thereof
WO2013049567A1 (en) 2011-09-29 2013-04-04 The Broad Institute, Inc. Compounds for the treatment of mycobacterial infections
EP2765860B1 (en) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013059278A2 (en) 2011-10-17 2013-04-25 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2013074387A1 (en) 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
IN2014CN04676A (da) 2011-12-21 2015-09-18 Ono Pharmaceutical Co
NZ629795A (en) 2012-02-02 2016-06-24 Actelion Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
US9047780B2 (en) 2012-11-16 2015-06-02 Robert Bosch Gmbh Collision mitigation systems and methods using driver attentiveness
WO2014081280A2 (en) 2012-11-21 2014-05-30 Lim Pooi Nguon Information medium and a method of producing the same
CN103848819B (zh) 2012-11-29 2017-04-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
CN103880823B (zh) 2012-12-21 2017-12-05 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
JP2016511220A (ja) 2013-02-13 2016-04-14 住友化学株式会社 有害生物防除組成物およびその用途
AU2014223501A1 (en) 2013-02-28 2015-09-17 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CN111116563B (zh) 2013-06-06 2023-07-04 上海爱博医药科技有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
WO2015004534A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
US9586944B2 (en) 2013-07-15 2017-03-07 The Scripps Research Institute Specific targeting of RNA expanded repeat sequences
WO2015031819A1 (en) 2013-08-29 2015-03-05 The Scripps Research Institute Modularly assembled small molecules for the treatment of myotonic dystrophy type 1
WO2015042438A1 (en) 2013-09-19 2015-03-26 The Florida International Board Of Trustees Modesto A. Maidique Campus Selective inhibition of bacterial topoisomerase i
SG11201602815YA (en) 2013-10-11 2016-05-30 Genentech Inc Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
JP6217317B2 (ja) 2013-10-30 2017-10-25 株式会社リコー 色素増感太陽電池
CN104610272B (zh) 2013-11-05 2017-03-29 上海唐润医药科技有限公司 环状黄酮或异黄酮类化合物及其用途
CN103728294B (zh) 2013-12-17 2016-05-11 中国科学院化学研究所 二苯并咪唑联咔唑类化合物在用于特异性结合核酸g-四链体结构及在抗肿瘤药物中的应用
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN103952009B (zh) 2014-05-08 2015-12-30 中国工程物理研究院化工材料研究所 一种近红外宽光谱金属配合物染料及其制备方法
PL408251A1 (pl) 2014-05-19 2015-11-23 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
CN104030988B (zh) 2014-06-25 2016-07-06 上海道亦化工科技有限公司 一种基于苯并咪唑的电子传输化合物
CN104193738B (zh) 2014-08-21 2016-05-18 上海道亦化工科技有限公司 一种基于苯并咪唑的电子传输化合物
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
US20190055235A1 (en) 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
WO2016097863A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Inhibitors of bromodomains
CN104710410B (zh) 2015-01-23 2017-10-10 固安鼎材科技有限公司 一种联苯并咪唑衍生物、其制备方法及其应用
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
HUE056334T2 (hu) 2022-02-28
JP6871864B2 (ja) 2021-05-19
CN107750249A (zh) 2018-03-02
WO2016170324A1 (en) 2016-10-27
ES2888473T3 (es) 2022-01-04
EP3286183A1 (en) 2018-02-28
GB201506658D0 (en) 2015-06-03
JP2018519249A (ja) 2018-07-19
EP3286183B1 (en) 2021-08-25
US20180127402A1 (en) 2018-05-10
US10118920B2 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
NL301311I2 (nl) sugemalimab
FIC20240028I1 (fi) Retifanlimabi
NL301216I2 (nl) vutrisiran
FIC20240040I1 (fi) Krovalimabi
DK3286183T3 (da) Isoxazolylsubstituerede benzimidazoler
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3331528T3 (da) Muskarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
EP3363322A4 (en) Hair extender
DK3292136T3 (da) Penicillin-g-acylaser
DK3274482T3 (da) Stenborsknop
DE112015006486A5 (de) Inkubationsrinne
EP3548009A4 (en) POLYMERIC NANOPARTICLES
DK3318308T3 (da) Badmintonketsjer
DE112015005904A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill